Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

LB PHARMACEUTICALS INC Director's Dealing 2025

Sep 11, 2025

33183_dirs_2025-09-10_50d6af90-fd3a-4ee9-9723-e8612c22d8df.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: LB PHARMACEUTICALS INC (LBRX)
CIK: 0001691082
Period of Report: 2025-09-10

Reporting Person: PRENSKY ZACHARY (N/A)

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 315 Direct
Common Stock 60959 Indirect

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Employee Stock Option (Right to Buy) $64.15 2028-11-13 Common Stock (3944) Direct
Employee Stock Option (Right to Buy) $69.72 2029-12-22 Common Stock (896) Direct
Employee Stock Option (Right to Buy) $69.72 2030-08-30 Common Stock (1255) Direct
Employee Stock Option (Right to Buy) $41.84 2033-08-24 Common Stock (17929) Direct
Employee Stock Option (Right to Buy) $41.84 2034-06-26 Common Stock (53787) Direct

Footnotes

F1: The securities are held by The Kybartai Trust, of which the Reporting Person is both a trustee and partial beneficiary. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

F2: Immediately exercisable.

F3: One fourth (1/4) of the shares subject to the option award vested on August 25, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

F4: One fourth (1/4) of the shares subject to the option award vested on June 28, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.